document type sequence filename description text html head title title head body bgcolor white style margin margin bottom font size font family time roman align right exhibit style margin margin bottom font size font family time roman align center confidential treatment requested bind therapeutic style margin margin bottom font size font family time roman align center second amendment research option license agreement style margin margin bottom text indent font size font family time roman this second amendment research option license agreement this amendment entered into march nbsp second amendment effective date between bind therapeutic successor interest bind bioscience bind pfizer pfizer amends that certain research option license agreement between bind bioscience pfizer dated march nbsp agreement amended restated june nbsp capitalized term used herein without definition herein shall have meaning given such term agreement style margin margin bottom text indent font size font family time roman small hereas small small small bind pfizer desire adjust design preclinical collaboration term allow additional activity conducted with respect agreement compound agreement compound style margin margin bottom text indent font size font family time roman small small small therefore small small small bind pfizer good valuable consideration receipt sufficiency which hereby mutually acknowledged intending legally bound hereby agree follows style margin margin bottom font size font family time roman section agreement hereby deleted entirety replaced with following style margin margin bottom text indent font size font family time roman party will conduct design preclinical collaboration project term condition forth this agreement design preclinical collaboration plan identify develop agreement compound design preclinical collaboration project will undertaken performed during period beginning effective date ending september nbsp unless earlier terminated provided this agreement design preclinical collaboration term except that only with respect activity conducted thereunder with respect agreement compound design preclinical collaboration project will extended until march nbsp unless earlier terminated provided this agreement design preclinical collaboration term extended only mutual written agreement party style margin margin bottom font size font family time roman section nbsp agreement hereby deleted entirety replaced with following style margin margin bottom text indent font size font family time roman pfizer option period commencing effective date ending march nbsp option period pfizer will entitled written notice bind option notice exercise option period commencing effective date ending september nbsp option period pfizer will entitled written notice bind option notice exercise option option notice option notice sometimes each referred option notice option period option period sometimes each referred option period style margin margin bottom text indent font size font family time roman clarity section nbsp through nbsp remain unchanged style margin margin bottom font size font family time roman party hereby consent issue press release attached herein exhibit style margin margin bottom font size font family time roman align center confidential portion this exhibit marked have been omitted pursuant request confidential treatment have been filed separately with security exchange commission style page break before always size style color width align center style margin margin bottom font size font family time roman align center confidential treatment requested bind therapeutic style margin margin bottom font size nbsp style margin margin bottom font size font family time roman this amendment shall become effective second amendment effective date except amended hereby term condition agreement shall remain full force effect other respect unless further amended written agreement this amendment executed number counterpart each which when executed delivered shall deemed original such counterpart together shall constitute same instrument signature page attached from multiple separate counterpart attached single counterpart that signature page physically attached same document style margin margin bottom font size font family time roman witness whereof each party hereto caused this amendment duly executed name behalf effective second amendment effective date style font size margin margin bottom nbsp align right table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width style font family time roman font size valign colspan bind small herapeutics small small small style font size height height colspan style font family time roman font size valign valign bottom valign style margin margin bottom border bottom solid font size font family time roman andrew hirsch style font size height height colspan style font family time roman font size valign name valign bottom valign style margin margin bottom border bottom solid font size font family time roman andrew hirsch style font size height height colspan style font family time roman font size valign title valign bottom valign style margin margin bottom border bottom solid font size font family time roman president style font size height height colspan style font family time roman font size valign date valign bottom valign style margin margin bottom border bottom solid font size font family time roman april style font size height colspan style font family time roman font size valign colspan small fizer small small small style font size height height colspan style font family time roman font size valign valign bottom valign style margin margin bottom border bottom solid font size font family time roman steven adam style font size height height colspan style font family time roman font size valign name valign bottom valign style margin margin bottom border bottom solid font size font family time roman steven adam style font size height height colspan style font family time roman font size valign title valign bottom valign style margin margin bottom border bottom solid font size font family time roman exec portfolio mgmt style font size height height colspan style font family time roman font size valign date valign bottom valign style margin margin bottom border bottom solid font size font family time roman march nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center confidential portion this exhibit marked have been omitted pursuant request confidential treatment have been filed separately with security exchange commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center confidential treatment requested bind therapeutic style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style font size margin margin bottom nbsp style font size margin margin bottom nbsp style margin margin bottom logo style margin margin bottom font size font family time roman align center bind therapeutic announces extension global collaboration with pfizer develop commercialize multiple accurins style margin margin bottom font size font family time roman align center progress made preclinical research collaboration goal track style margin margin bottom font size font family time roman cambridge mass march bind therapeutic nasdaq bind clinical stage nanomedicine platform company developing targeted programmable therapeutic called accurins today announced extension term global collaboration with pfizer create accurins that optimize therapeutic potential molecularly targeted oncology drug pfizer pipeline collaboration originally established april timeline pfizer exercise option acquire exclusive license first program continues september both company agreed extension timeline second program through march style margin margin bottom font size font family time roman have made great deal progress this collaboration have shown promising preclinical result with accurins containing each compound said andrew hirsch president chief executive officer bind therapeutic pfizer been terrific partner result date have provided evidence that track with collaboration goal mutually agreed extend research term second selected compound order ensure fully evaluated well positioned enter enabling study style margin margin bottom font size font family time roman development milestone achieved first program december option target date first compound remains unchanged this extension allows bind pfizer additional year complete preclinical research evaluating second program style margin margin bottom font size font family time roman accurin development program active high interest both company said robert abraham senior vice president chief scientific officer oncology research unit pfizer pleased continue working with bind under term amended agreement style margin margin bottom font size font family time roman under term original agreement pfizer exclusive option pursue development commercialization accurins selected both company will work together preclinical research pfizer exercise option pfizer will have responsibility development commercialization selected accurins style margin margin bottom font size font family time roman bind received upfront payment million million preclinical development milestone december potential receive payment million upon style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align right draft style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center confidential portion this exhibit marked have been omitted pursuant request confidential treatment have been filed separately with security exchange commission style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center confidential treatment requested bind therapeutic style margin margin bottom font size nbsp style margin margin bottom font size font family time roman achievement additional specified development regulatory event bind also receive additional payment million specified commercial event well royalty single high single digit percentage potential future sale each accurin commercialized style margin margin bottom font size font family time roman about bind therapeutic style margin margin bottom font size font family time roman bind therapeutic clinical stage nanomedicine platform company developing pipeline accurins novel targeted therapeutic designed increase concentration duration therapeutic payload disease site while reducing exposure healthy tissue bind leveraging medicinal nanoengineering platform develop pipeline accurins targeting hematological solid tumor number strategic collaboration with biopharmaceutical company develop accurins area high unmet need bind lead drug candidate bind prostate specific membrane antigen psma targeted accurin that contains docetaxel clinically validated widely used cancer chemotherapy drug bind currently development treatment small cell lung cancer nsclc patient with kras mutation squamous histology addition bind plan initiate clinical trial with bind cervical bladder head neck cholangio cancer bind also advancing bind second psma targeted accurin drug candidate containing vincristine potent microtubule inhibitor with dose limiting peripheral neuropathy conventional form through important preclinical study position investigational drug application filing with food drug administration lastly bind developing accurins designed inhibit both which bind belief promising anti mitotic target that have been limited clinic myelotoxicity prior reaching therapeutic style margin margin bottom font size font family time roman bind announced ongoing collaboration with pfizer astrazeneca hoffmann roche merck nbsp merck known merck sharp nbsp dohme outside united state canada develop accurins based their proprietary therapeutic payload targeting ligand style margin margin bottom font size font family time roman forward looking statement disclaimer update style margin margin bottom font size font family time roman this press release contains forward looking statement within meaning private security litigation reform statement contained this press release that relate matter historical fact should considered forward looking statement including statement regarding intention regarding permanent chief executive officer belief that accurins have potential become major therapeutic modality goal gain approval first accurin nanomedicine advance build bind proprietary oncology pipeline apply bind technology therapeutic approach expectation regarding bind nanomedicine platform expectation regarding leadership team opportunity financial position style margin margin bottom font size font family time roman these forward looking statement based management current expectation these statement neither promise guarantee involve known unknown risk uncertainty other important factor that cause actual result performance achievement materially different from future result performance achievement expressed implied forward looking statement including limited following fact that company incurred significant loss since inception expects incur loss foreseeable future company need additional style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align right draft style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center confidential portion this exhibit marked have been omitted pursuant request confidential treatment have been filed separately with security exchange commission style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center confidential treatment requested bind therapeutic style margin margin bottom font size nbsp style margin margin bottom font size font family time roman funding which available raising additional capital cause dilution stockholder require relinquish right technology drug candidate company limited operating history failure expand medicinal nanoengineering platform build pipeline drug candidate develop marketable drug early stage company development effort with only drug candidate clinical development failure company collaborator successfully develop commercialize drug candidate clinical drug development involves lengthy expensive process with uncertain outcome delay difficulty enrollment patient clinical trial serious adverse unacceptable side effect limited efficacy observed during development company drug candidate inability maintain company collaboration failure these collaboration company reliance third party conduct clinical trial manufacture drug candidate company inability obtain required regulatory approval conclusion that bind satisfy requirement approval under section nbsp regulatory approval pathway inability obtain orphan drug exclusivity drug candidate failure obtain marketing approval international jurisdiction post marketing restriction withdrawal from market effect recently enacted future legislation failure comply with environmental health safety regulation failure achieve market acceptance physician patient third party payors failure establish effective sale marketing distribution capability enter into agreement with third party with such capability effect substantial competition unfavorable pricing regulation third party reimbursement practice healthcare reform initiative product liability lawsuit failure retain executive attract retain motivate qualified personnel difficulty managing growth risk associated with operating internationally including possibility sanction with respect operation russia failure obtain maintain patent protection otherwise protect technology product effect patent other intellectual property lawsuit eligibility significant portion company total outstanding share sold into market which could cause market price common stock drop significantly increased cost result operating public company security class action litigation these other important factor discussed under caption risk factor quarterly report form filed with security exchange commission november nbsp other report filed with could cause actual result differ materially from those indicated forward looking statement made this press release such forward looking statement represent management estimate date this press release while elect update such forward looking statement some point future disclaim obligation even subsequent event cause view change these forward looking statement should relied upon representing view date subsequent date this press release style margin margin bottom font size font family time roman medium style margin margin bottom font size font family time roman jeff boyle style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman medium bindtherapeutics style margin margin bottom font size font family time roman investor style margin margin bottom font size font family time roman baker style margin margin bottom font size font family time roman style margin margin bottom font size font family time roman investor bindtherapeutics style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align right draft style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center confidential portion this exhibit marked have been omitted pursuant request confidential treatment have been filed separately with security exchange commission style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center body html text document